Please wait while the transcript is being prepared...
0:00
Hello, my name is Peter Ebeling,
and I'm the head of the Department
of Medicine in the School for
Clinical Sciences at the Monash
Health Translation Precinct
in Victoria, Australia.
My Henry Stewart talk today
is about osteoporosis in men.
0:17
My potential conflicts
are listed here.
I receive departmental research
funding from Merck, Novartis,
Amgen, and Eli-Lilly,
and I've received
honoraria from Amgen and Merck.
0:28
Today, I'd like to discuss with you
epidemiology and mechanisms of bone
loss in men and the
importance of estradiol.
I'd like to review
the Endocrine Society
guidelines on osteoporosis in men.
I'd like to assess risk factors
for osteoporosis in men,
and review osteoporosis treatments
and gaps in our evidence base.
0:51
We've spent 20 years
studying osteoporosis in men.
And these are data
from Cyrus Cooper
when we were working
together at the Mayo Clinic.
These data show that with aging,
vertebral and hip fractures
increasing in men, but
colles fractures do not.
The number of hip fractures and
vertebral fractures occurring
in men are about half that
occurring with aging in women.
So it is an important
health problem.
1:16
In fact, one third of hip
fractures occur in men.
The increase in men
with hip fractures
is due to both an
increase in longevity
and a later-born or
secular increase.
However, now we're seeing that
age-related hip fracture incidence
rates in many Western countries
are increasing in women,
but not so much in men.
And the mortality rates after a
hip fracture in men are about 50%
higher than those in women at
a rate of 37.5% in 12 months.
